Intellia (NTLA) Beats on Q4 Earnings, Provides Pipeline Update

Intellia Therapeutics, Inc. (NTLA) reported fourth-quarter 2023 loss of $1.46 per share, narrower than the Zacks Consensus Estimate of a loss of $1.47. In the year-ago quarter, Intellia incurred a loss of $1.40 per share.The company’s total revenues currently comprise only collaboration revenues. NTLA reported negative revenues of $1.9 million during the fourth quarter of 2023 compared with $13.6 million reported in the year-ago quarter. The top line missed the Zacks Consensus Estimate of $15 million.The de ...